NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Bosch said pseudo progression "wreaks havoc with trials."

FWIW: looking back at evaluate's notes, Bosch also stated:

Marnix Bosch mentioned some issues about challenges in immunotherapy trials:
1. Pseudo progression wreaks havoc with trials
2. Might need to go to Overall Survival for primary trial endpoint in future trials, which could cause trials to take a lot longer.
3. Quality of Life - often QOL is improved, but currently blunt measurements of QOL .... Soft endpoint currently.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=120315677

note: "the others" were the other speakers. Dr. Bosch was the season chair.

Anyhow, I thought, looking back, that point #2 was interesting, as that seems to be what happened, although we never thought that it would at the time.